Suspect counterfeit Ozempic: verify identifiers and report concerns

What the current FDA warning establishes

A suspect Ozempic package calls for documentation, not a visual guess. FDA has identified counterfeit product in the U.S. drug supply chain and published specific lot, serial, and package-placement information. A match is a stop signal; a nonmatch is not a universal authenticity certificate. Preserve the package and transaction record, trace the dispensing channel, verify the pharmacy, and use the official reporting route that fits the concern.

The same warning tells people not to use, distribute, or sell products labeled with the counterfeit information identified by FDA. It reports uncertainty about the seized products' identity, quality, and safety and notes an increased infection risk from counterfeit needles. The cited evidence does not extend those statements to every Ozempic pen or predict what any specific suspect product contains. Its job is narrower: preserve the identifiers FDA published, show how to separate a warning match from a broader verification decision, and route documentation to official channels without creating a fake consumer certification system.

The current FDA warning lists three affected lot numbers: PAR1229, PAR0362, and NAR0074. It also identifies serial information beginning with 51746517 and the specific serial number 430834149057. Copy the characters exactly as printed, including their order, rather than relying on memory or a cropped marketplace image. Record where each identifier appears on the carton or pen, the expiration information beside it, the product description, and the quantity received. A clear photograph of the full face plus close images of each identifier creates a more useful record than a typed number alone.

An identifier match is a stop signal under the warning. It is not permission to keep using the product while waiting for informal confirmation, and it is not something a seller can neutralize with a text message. Conversely, an identifier that doesn't match this list is not proof that the package is authentic. FDA warnings describe evidence known at a point in time; counterfeiters can change numbers, labels, and channels. Reopen the current FDA warning when checking a real product because the agency can update identifiers, images, instructions, or the investigation status after the cited evidence's July 23, 2026 source check.

Copy the lot, serial, and package details exactly

FDA describes a visible placement difference in the affected products. On the counterfeit products in the warning, the EXP/LOT text appears on the left side of the expiration date and lot number. FDA says authentic Ozempic pens have the EXP/LOT text above the expiration date and lot number. Photograph the relevant panel straight on, in enough light to read the text, without editing or applying filters. Preserve a wider image showing which package or pen the close-up belongs to. That reduces the chance that a detached image is later confused with another item.

Treat this as a warning-specific comparison, not a complete authentication test. Packaging can vary by market, product presentation, and time, and FDA doesn't say that one layout check proves every other feature is genuine. Do not invent additional telltales from color, font weight, needle appearance, box texture, or online side-by-side graphics unless a current cited source supports them. A mismatch can justify escalation; a match to one expected feature doesn't close the case. Channel, license, reviewed sources, manufacturer contact, and current FDA information remain part of the evidence decision.

Trace the product back to the dispensing pharmacy

FDA's counterfeit-medicine guidance says consumers should buy from state-licensed pharmacies. The current Ozempic warning also says Ozempic should be obtained only with a valid prescription through state-licensed pharmacies. Record the pharmacy's legal name, physical location, website or app used, prescription record, order date, transaction amount, and dispensing label. A brand-like website name is not the same thing as a pharmacy license. A telehealth intake, marketplace listing, social account, payment link, or shipping label also doesn't substitute for the dispensing pharmacy's identity and license status.

Use the FDA BeSafeRx state-license path to reach the relevant state board of pharmacy record, then compare the legal business name and location with the dispensing information. Check both the state where the pharmacy operates and the requirements relevant to the buyer's state. Save the result date and the record used. A license record is strong channel evidence but still doesn't authenticate one physical package. If the seller will not identify the dispensing pharmacy, the license can't be found, or the names and locations don't reconcile, preserve that discrepancy instead of filling the gap with a guess.

A useful record can be small: full carton photographs, pen photographs, close images of lot, serial, expiration, and EXP/LOT placement, the dispensing label with unnecessary personal details redacted for sharing, receipt or transaction record, pharmacy legal name, state-license lookup result, order and delivery dates, seller or platform URL, and a short factual timeline. Keep the original files. If creating a review copy, note what was redacted or resized. Do not alter the identifiers, replace backgrounds, or combine images in a way that hides which surface they came from.

Write observations, not conclusions. For example: 'Carton shows lot PAR1229; photograph captured July 23' is stronger than 'This is definitely fake' unless a cited source has made that determination. 'EXP/LOT text appears to the left of the date' is more reviewable than 'Packaging looks wrong.' Record who dispensed the product and which official page was checked. Keep seller promises, chats, or advertisements as separate evidence. This structure lets the pharmacy, manufacturer, FDA, or another authorized reviewer inspect the same facts without depending on the consumer's theory.

When the warning information matches

FDA's instruction is direct: don't use, distribute, or sell products labeled with the counterfeit information in the warning. Keep the item and packaging available for the next official instruction rather than passing it to another person or returning it through an unverified seller workflow that could put it back into circulation. Contact the dispensing pharmacy and explain the exact lot, serial, and packaging observations. FDA's warning also gives Novo Nordisk customer care as a contact for authenticity concerns. Record the date, channel, case number, and factual response from each contact.

The cited evidence does not provide storage, handling, disposal, replacement, or medical instructions for a suspect product. Those depend on current direction from the dispensing pharmacy, manufacturer, FDA, or an appropriate licensed professional. It also doesn't tell a person whether an observed event came from a counterfeit product. If there is an adverse event or side-effect concern, FDA provides the MedWatch reporting program; the report should describe what happened and identify the suspect product without asking an informational summary to interpret causation. Preserve official case numbers so later reports can be connected accurately.

Choose the reporting route that fits the concern

FDA identifies several routes with different purposes. Suspected counterfeit products can be reported to a local FDA consumer complaint coordinator. Adverse events or side effects can be reported through the MedWatch Safety Information and Adverse Event Reporting Program; the current warning says reports can be submitted online or by fax to 1-800-FDA-0178. FDA's counterfeit-medicine guidance also points to reporting unsafe online pharmacy sales and suspected criminal counterfeit activity through the appropriate FDA channels. Don't assume that one report automatically performs every other function.

Match the record to the route. A product complaint should foreground identifiers, packaging, channel, license, and transaction evidence. An unsafe online pharmacy report should preserve the website, seller identity, claimed pharmacy, payment path, prescription behavior, and license discrepancy. A MedWatch report should follow the program's requested event and product fields rather than turning a packaging concern into an unsupported medical conclusion. Criminal-activity reporting should preserve seller communications and transaction facts. Save submission confirmations and report numbers; they are evidence that a route was used, not proof of FDA's final determination.

Check the pharmacy before paying and separate product-status questions

The most reversible checkpoint occurs before a transaction. FDA's online-pharmacy guidance identifies state-board licensing as a sign of a safer legal pharmacy and provides BeSafeRx resources for license lookup. Before paying, identify the actual dispensing pharmacy, find its state-board record, compare legal names and locations, confirm that a valid prescription is required, and preserve the current offer terms. If the site hides the dispensing entity, offers prescription medicine without a valid prescription, or uses a license identity that doesn't match the transaction, stop the checkout review rather than treating a discount as compensation for missing evidence.

This doesn't turn Clinic Scout or a buyer into a pharmacy regulator. The checklist produces a documented channel decision. It can't prove the future contents of a shipment or guarantee that a licensed participant will never receive a counterfeit item. That is why post-delivery package and identifier checks still matter. It also can't determine whether a compounded semaglutide product is counterfeit Ozempic: a compounded product and an FDA-approved branded Ozempic product have different product-status questions. Don't use the Ozempic logo, active-ingredient name, or similar packaging language to erase that distinction.

Counterfeit is not a catch-all word for every product that is not an FDA-approved Ozempic pen. FDA's warning concerns products passed off as Ozempic and labeled with specific counterfeit information. A compounded semaglutide product is not FDA-approved Ozempic, but that product-status difference alone doesn't establish criminal counterfeiting. An illegally marketed product, a misbranded offer, a shipping error, and a package with a quality complaint can also require different evidence and reporting routes. Use the narrowest supported label in notes until a cited source makes a stronger determination.

This distinction prevents two failures. First, it avoids granting legitimacy to an offer that uses the word 'compounded' while imitating a branded product or hiding its pharmacy. Second, it avoids accusing a legitimate compounding pharmacy or seller of counterfeiting without evidence. Record exactly what the offer claimed, what the label says, what entity dispensed it, and whether the product was represented as Ozempic. FDA product-status and online-pharmacy resources can support separate checks, but the cited evidence does not decide regulatory classification for an individual transaction.

Build a traceable verification record

Use ten fields for each review: product as represented; physical product received; lot number; serial number; expiration and EXP/LOT placement; dispensing pharmacy legal name; state-board license record and check date; prescription and transaction record; FDA warning version and check date; contacts, submissions, and case numbers. Add a status beside each field: documented, missing, mismatched, or pending official response. This makes the record scannable and prevents one reassuring field from hiding several unanswered ones.

The checklist supports a decision to escalate, not a self-issued certificate. A package can have documented identifiers and still be pending manufacturer review. A pharmacy license can be valid while the source of one product remains under investigation. An FDA report can be accepted while the agency's determination remains open. Preserve those states. If facts change, append a dated update rather than rewriting the original entry. The goal is a traceable chain from offer to dispenser to physical package to official report, with uncertainty visible instead of edited away.

What a package check can and cannot conclude

Does a different lot number prove an Ozempic pen is authentic? No. It only means the package doesn't match that identifier from the current warning. Does the EXP/LOT position prove authenticity? No; it is one warning-specific visual check. Can a licensed pharmacy record authenticate a pen? No. It strengthens channel evidence. Should a warning-matching product be used, distributed, or sold? FDA says no. Can a seller's refund promise replace reporting? No. Preserve the transaction and use the official route appropriate to the product, pharmacy, adverse event, or suspected criminal activity.

Sources were checked through July 23, 2026: the FDA counterfeit Ozempic warning, FDA counterfeit-medicine guidance, and FDA BeSafeRx state-license resources. Reopen them for a real check because identifiers and instructions can change. It doesn't determine authenticity, diagnose exposure, attribute an adverse event, direct medical care, replace a pharmacist or regulator, or guarantee that a report will produce a particular outcome.